🇺🇸 FDA
Patent

US 9770414

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

granted A61KA61K31/198A61K31/25

Quick answer

US patent 9770414 (Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent) held by Pacira Pharmaceuticals, Inc. expires Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Pacira Pharmaceuticals, Inc.
Grant date
Tue Sep 26 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 21 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
65
CPC classes
A61K, A61K31/198, A61K31/25, A61K31/519, A61K31/575